Wedbush Maintains Outperform on ORIC Pharmaceuticals, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten maintains an Outperform rating on ORIC Pharmaceuticals (NASDAQ:ORIC) and raises the price target from $12 to $20.
March 01, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten maintains an Outperform rating on ORIC Pharmaceuticals and raises the price target from $12 to $20.
The increase in price target by a reputable analyst suggests a strong bullish outlook on ORIC Pharmaceuticals, likely leading to positive investor sentiment and a potential short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100